secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACELYRIN, Inc. (—)
CIK:        0001962918
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001193125-24-134812
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ACELYRIN appoints Mina Kim as CEO; founder Lin steps down; cash $678.5M
-----------------------------------------------------------------------

- Mina Kim appointed CEO and board member effective May 9; Shao-Lee Lin steps down as CEO and from board.
- Cash, cash equivalents and short-term marketable securities total $678.5M at March 31, 2024; funding into 2026 reiterated.
- Izokibep Phase 3 HS trial enrollment completed (258 patients); top-line data expected Q3 2024.
- Positive proof-of-concept for lonigutamab in thyroid eye disease; Phase 2b/3 trial planned H2 2024.
- Company will not host Q1 2024 earnings call; 10-Q to be filed by May 14, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962918/000119312524134812/0001193125-24-134812-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962918/000119312524134812/d799182d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-134812

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer